|
|
AS01 |
|
Vaxjo ID |
334 |
|
Vaccine Adjuvant Name |
AS01 |
|
Description |
AS01 is an adjuvant system composed of a TLR4 ligand, 3-O-desacyl-4'-monophosphoryl lipid A (MPL), and a saponin, QS-21. It promotes an early IFN纬 response that is essential for the activation of dendritic cells and the development of Th1 immunity by AS01-adjuvanted vaccine. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
TLR4 ligand, 3-O-desacyl-4'-monophosphoryl lipid A (MPL), and a saponin, QS-21, the constituents of the adjuvant System AS01. |
|
Structure |
Composed of a TLR4 ligand, 3-O-desacyl-4'-monophosphoryl lipid A (MPL), and a saponin, QS-21. |
|
Function |
AS01, used in malaria and herpes zoster vaccines, triggers early IFN-γ release by NK and CD8+ T cells in lymph nodes shortly after injection. This response, driven by MPL and QS-21 synergy and regulated by macrophages, IL-12, and IL-18, is crucial for dendritic cell activation and Th1 immunity development. |
| References |
Coccia et al., 2017: Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Deun KV, Smilde AK, Berg RAVD, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, Most RV, Didierlaurent AM. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ vaccines. 2017; 2; 25. [PubMed: 29263880].
|
|
